A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients With Advanced Solid Tumors With Liver Involvement.
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2013
At a glance
- Drugs ALN-VSP (Primary)
- Indications Liver cancer; Liver metastases; Solid tumours
- Focus Adverse reactions
- 30 Jan 2013 Results were published online in Cancer Discovery, according to an Alnylam Pharmaceuticals media release.
- 15 May 2012 Final results will be presented at the Annual Meeting of the American Society of Clinical Oncology in June 2012.
- 09 Feb 2012 Interim results from the first three patients enrolled in the extension protocol have been presented in an Alnylam Pharmaceuticals media release.